Cargando…

Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS

PURPOSE: The aim of this report is dosimetric evaluation for an intraoperative fusion computed tomography (CT) as a superior predictor of 1-month CT based dosimetry in comparison to transrectal ultrasound (TRUS) in permanent interstitial prostate brachytherapy. MATERIAL AND METHODS: Data of 65 patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishiyama, Hiromichi, Sekiguchi, Akane, Satoh, Takefumi, Tsumura, Hideyasu, Takenaka, Kouji, Kawakami, Shogo, Tabata, Ken-ichi, Kobayashi, Kentaro, Iwamura, Masatsugu, Hayakawa, Kazushige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2016
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793069/ https://www.ncbi.nlm.nih.gov/pubmed/26985192 http://dx.doi.org/10.5114/jcb.2016.57817

Ejemplares similares

Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy
por: Kawakami, Shogo, et al.
Publicado: (2017)

A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial
por: Ishiyama, Hiromichi, et al.
Publicado: (2018)

Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2017)

Comparison of three different techniques of low-dose-rate seed implantation for prostate cancer
por: Ishiyama, Hiromichi, et al.
Publicado: (2015)

(125)Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up
por: Sekiguchi, Akane, et al.
Publicado: (2014)

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2016)

A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
por: Kainuma, Takuro, et al.
Publicado: (2019)

Catheter displacement prior to the delivery of high-dose-rate brachytherapy in the treatment of prostate cancer patients
por: Kawakami, Shogo, et al.
Publicado: (2014)

High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up
por: Ishiyama, Hiromichi, et al.
Publicado: (2014)

Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients
por: Fujii, Kyohei, et al.
Publicado: (2023)

Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
por: Tabata, Ken-ichi, et al.
Publicado: (2012)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Networld and Interop Conference
Publicado: (1995)

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

MRI‐TRUS registration methodology for TRUS‐guided HDR prostate brachytherapy
por: McGeachy, Philip, et al.
Publicado: (2021)

A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
por: Kawakami, S., et al.
Publicado: (2022)

Networld and Interop Engineers Conference
Publicado: (1996)

Assessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy?
por: Soda, Itaru, et al.
Publicado: (2015)

Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer
por: Yanagisawa, Nobuyuki, et al.
Publicado: (2021)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy
por: Ishiyama, Hiromichi, et al.
Publicado: (2016)

Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning
por: Lavoie-Gagnon, Heloise, et al.
Publicado: (2022)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

Imaging Cherenkov emission for quality assurance of high-dose-rate brachytherapy
por: Yogo, Katsunori, et al.
Publicado: (2020)

Dosimetric factors associated with long-term patient-reported outcomes after definitive radiotherapy of patients with head and neck cancer
por: Hayakawa, Toyokazu, et al.
Publicado: (2019)

Effect of constipation on dosimetry after permanent seed brachytherapy for prostate cancer
por: Otón, L. Fernando, et al.
Publicado: (2015)

Hybrid TRUS/CT with optical tracking for target delineation in image-guided adaptive brachytherapy for cervical cancer
por: Smet, Stéphanie, et al.
Publicado: (2020)

Spectral clustering for TRUS images
por: Mohamed, Samar S, et al.
Publicado: (2007)

Classification of Focal Prostatic Lesions on Transrectal Ultrasound (TRUS) and the Accuracy of TRUS to Diagnose Prostate Cancer
por: Lee, Ho Yun, et al.
Publicado: (2009)

Quality of life score as a prognosticator for pharyngeal cancer patients treated with radiotherapy
por: Ishiyama, Hiromichi, et al.
Publicado: (2022)

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Prospective intra/inter-observer evaluation of pre-brachytherapy cervical cancer tumor width measured in TRUS and MR imaging
por: Federico, Mario, et al.
Publicado: (2019)

Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study
por: Kawahara, Takashi, et al.
Publicado: (2020)

Golden Standard: a complete standard, portable, and interoperative MoClo tool for model and non-model proteobacteria
por: Blázquez, Blas, et al.
Publicado: (2023)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

Influence of zonal dosimetry on prostate brachytherapy outcomes
por: Hong, Cheng William, et al.
Publicado: (2015)

Improved prostate delineation in prostate HDR brachytherapy with TRUS‐CT deformable registration technology: A pilot study with MRI validation
por: Yang, Xiaofeng, et al.
Publicado: (2017)

Influence of body mass index and periprostatic fat on rectal dosimetry in permanent seed prostate brachytherapy
por: Tiberi, David, et al.
Publicado: (2014)

Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer
por: Mori, Kohei, et al.
Publicado: (2023)

Dosimetry advantages of intraoperatively built custom-linked seeds compared with loose seeds in permanent prostate brachytherapy
por: Inada, Masahiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0v0tp8ie0qjmjjtm3u2i20i0gh